A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma.

Yoshinori Fujishiro, Kazunari Nakao, Kenta Watanabe, Yasuhiro Ebihara, Naoki Nakamura, Harushi Mori, Naoto Hayashi, Takahiro Asakage
{"title":"A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma.","authors":"Yoshinori Fujishiro,&nbsp;Kazunari Nakao,&nbsp;Kenta Watanabe,&nbsp;Yasuhiro Ebihara,&nbsp;Naoki Nakamura,&nbsp;Harushi Mori,&nbsp;Naoto Hayashi,&nbsp;Takahiro Asakage","doi":"10.1080/03655230701599842","DOIUrl":null,"url":null,"abstract":"<p><strong>Conclusion: </strong>This superselective intra-arterial intervention technique enabled us to administer a higher dose of cisplatinum to the local lesion with a lower incidence of adverse issues by use of neutralizer, compared with the conventional methods.</p><p><strong>Objective: </strong>A wide variety of modalities, including surgery, radiotherapy, and chemotherapy, alone or in combination, have been reported for the treatment of maxillary sinus cancer. However, there is still much controversy with regard to the optimum treatment to obtain better local control and acceptable preservation of shape and function. Since 2001, we have performed superselective intra-arterial infusion chemotherapy in combination with radiotherapy and surgery aiming at a higher local control rate.</p><p><strong>Patients and methods: </strong>This was a review of prospective collected data. The therapeutic design consisted of weekly intra-arterial infusion of high dose CDDP with concomitant radiotherapy and planned surgery performed during chemo-radiation therapy. From June 2001 to January 2004, 14 patients with squamous cell carcinoma of maxillary sinus underwent this treatment procedure at the University of Tokyo Hospital.</p><p><strong>Results: </strong>The local response rate with this combined therapy was 85.7%. Overall survival rates at 1 and 2 years were 78.6% and 56.2%, respectively, with median follow-up of 25.5 months.</p>","PeriodicalId":7027,"journal":{"name":"Acta oto-laryngologica. Supplementum","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2007-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/03655230701599842","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta oto-laryngologica. Supplementum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/03655230701599842","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Conclusion: This superselective intra-arterial intervention technique enabled us to administer a higher dose of cisplatinum to the local lesion with a lower incidence of adverse issues by use of neutralizer, compared with the conventional methods.

Objective: A wide variety of modalities, including surgery, radiotherapy, and chemotherapy, alone or in combination, have been reported for the treatment of maxillary sinus cancer. However, there is still much controversy with regard to the optimum treatment to obtain better local control and acceptable preservation of shape and function. Since 2001, we have performed superselective intra-arterial infusion chemotherapy in combination with radiotherapy and surgery aiming at a higher local control rate.

Patients and methods: This was a review of prospective collected data. The therapeutic design consisted of weekly intra-arterial infusion of high dose CDDP with concomitant radiotherapy and planned surgery performed during chemo-radiation therapy. From June 2001 to January 2004, 14 patients with squamous cell carcinoma of maxillary sinus underwent this treatment procedure at the University of Tokyo Hospital.

Results: The local response rate with this combined therapy was 85.7%. Overall survival rates at 1 and 2 years were 78.6% and 56.2%, respectively, with median follow-up of 25.5 months.

上颌窦癌超选择性动脉化疗三模式治疗的新进展。
结论:与传统方法相比,这种超选择性动脉内介入技术使我们能够在使用中和剂的情况下对局部病变给予更高剂量的顺铂,并且不良事件的发生率更低。目的:多种治疗方式,包括手术、放疗和化疗,单独或联合治疗上颌窦癌已被报道。然而,关于获得更好的局部控制和可接受的形状和功能保存的最佳治疗方法仍然存在许多争议。自2001年起,我们开展了超选择性动脉内灌注化疗联合放疗和手术,旨在提高局部控制率。患者和方法:这是对前瞻性收集数据的回顾。治疗设计包括每周动脉内输注高剂量CDDP,同时进行放射治疗和化疗期间的计划手术。从2001年6月到2004年1月,14例上颌窦鳞状细胞癌患者在东京大学医院接受了这种治疗。结果:局部有效率为85.7%。1年和2年总生存率分别为78.6%和56.2%,中位随访时间为25.5个月。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信